tetano
Editor, Senior Moderator
Clin Microbiol Infect
. 2023 Apr 11;S1198-743X(23)00153-2.
doi: 10.1016/j.cmi.2023.04.001. Online ahead of print.
Outcomes of immunocompromised children hospitalized for influenza, 2010-2021, the Canadian Immunization Monitoring program active (IMPACT)
Tilmann Schober[SUP] 1 [/SUP], Shaun K Morris[SUP] 2 [/SUP], Julie A Bettinger[SUP] 3 [/SUP], Christina Bancej[SUP] 4 [/SUP], Catherine Burton[SUP] 5 [/SUP], Cheryl Foo[SUP] 6 [/SUP], Scott A Halperin[SUP] 7 [/SUP], Taj Jadavji[SUP] 8 [/SUP], Kescha Kazmi[SUP] 2 [/SUP], Jacqueline Modler[SUP] 9 [/SUP], Manish Sadarangani[SUP] 10 [/SUP], Jesse Papenburg[SUP] 11 [/SUP]; Canadian Immunization Monitoring Program Active (IMPACT) Investigators
Collaborators, Affiliations
Abstract
Objectives: To evaluate immunocompromising conditions and subgroups of immunocompromise as risk factors for severe outcomes among children admitted for influenza.
Methods: We performed active surveillance for laboratory-confirmed influenza hospitalizations among children ≤16 years old at the 12 Canadian Immunization Monitoring Program Active hospitals, during 2010-2021. Logistic regression analyses were used to compare outcomes between immunocompromised and non-immunocompromised children, and for different subgroups of immunocompromise. The primary outcome was intensive care unit (ICU) admission; secondary outcomes were mechanical ventilation and death.
Results: Among 8982 children, 892 (9.9%) were immunocompromised; these patients were older (median 5.6 [IQR 3.1 - 10.0] vs 2.4 [1 -6] years, p<0.001) than non-immunocompromised children, had similar frequency of comorbidities excluding immunocompromise and/or malignancy (38% [340/892) vs 40% [3272/8090], p=0.2), but fewer respiratory symptoms, such as respiratory distress (20% [177/892] vs 42% [3424/8090], p<0.001). In multivariable analyses, immunocompromise (adjusted odds ratio [aOR] 0.19, 95% CI 0.14-0.25) and its subcategories immunodeficiency (aOR 0.16, 95% CI 0.10-0.23), immunosuppression (aOR 0.17, 95% CI 0.12-0.23), chemotherapy (aOR 0.07, 95% CI 0.03-0.13) and solid organ transplantation (aOR 0.17, 95% CI 0.06-0.37) were associated with decreased probability of ICU admission in children admitted for influenza. Immunocompromise was also associated with decreased probability for mechanical ventilation (aOR 0.26, 95% CI 0.16-0.38) or death (aOR 0.22, 95% CI 0.03-0.72).
Conclusions: Immunocompromised children are overrepresented among hospitalizations for influenza, but have decreased probability of ICU admission, mechanical ventilation, and mortality following admission. Admission bias precludes generalizability beyond the hospital setting.
. 2023 Apr 11;S1198-743X(23)00153-2.
doi: 10.1016/j.cmi.2023.04.001. Online ahead of print.
Outcomes of immunocompromised children hospitalized for influenza, 2010-2021, the Canadian Immunization Monitoring program active (IMPACT)
Tilmann Schober[SUP] 1 [/SUP], Shaun K Morris[SUP] 2 [/SUP], Julie A Bettinger[SUP] 3 [/SUP], Christina Bancej[SUP] 4 [/SUP], Catherine Burton[SUP] 5 [/SUP], Cheryl Foo[SUP] 6 [/SUP], Scott A Halperin[SUP] 7 [/SUP], Taj Jadavji[SUP] 8 [/SUP], Kescha Kazmi[SUP] 2 [/SUP], Jacqueline Modler[SUP] 9 [/SUP], Manish Sadarangani[SUP] 10 [/SUP], Jesse Papenburg[SUP] 11 [/SUP]; Canadian Immunization Monitoring Program Active (IMPACT) Investigators
Collaborators, Affiliations
- PMID: 37054913
- DOI: 10.1016/j.cmi.2023.04.001
Abstract
Objectives: To evaluate immunocompromising conditions and subgroups of immunocompromise as risk factors for severe outcomes among children admitted for influenza.
Methods: We performed active surveillance for laboratory-confirmed influenza hospitalizations among children ≤16 years old at the 12 Canadian Immunization Monitoring Program Active hospitals, during 2010-2021. Logistic regression analyses were used to compare outcomes between immunocompromised and non-immunocompromised children, and for different subgroups of immunocompromise. The primary outcome was intensive care unit (ICU) admission; secondary outcomes were mechanical ventilation and death.
Results: Among 8982 children, 892 (9.9%) were immunocompromised; these patients were older (median 5.6 [IQR 3.1 - 10.0] vs 2.4 [1 -6] years, p<0.001) than non-immunocompromised children, had similar frequency of comorbidities excluding immunocompromise and/or malignancy (38% [340/892) vs 40% [3272/8090], p=0.2), but fewer respiratory symptoms, such as respiratory distress (20% [177/892] vs 42% [3424/8090], p<0.001). In multivariable analyses, immunocompromise (adjusted odds ratio [aOR] 0.19, 95% CI 0.14-0.25) and its subcategories immunodeficiency (aOR 0.16, 95% CI 0.10-0.23), immunosuppression (aOR 0.17, 95% CI 0.12-0.23), chemotherapy (aOR 0.07, 95% CI 0.03-0.13) and solid organ transplantation (aOR 0.17, 95% CI 0.06-0.37) were associated with decreased probability of ICU admission in children admitted for influenza. Immunocompromise was also associated with decreased probability for mechanical ventilation (aOR 0.26, 95% CI 0.16-0.38) or death (aOR 0.22, 95% CI 0.03-0.72).
Conclusions: Immunocompromised children are overrepresented among hospitalizations for influenza, but have decreased probability of ICU admission, mechanical ventilation, and mortality following admission. Admission bias precludes generalizability beyond the hospital setting.